- /
- Supported exchanges
- / US
- / ENTA.NASDAQ
Enanta Pharmaceuticals Inc (ENTA NASDAQ) stock market data APIs
Enanta Pharmaceuticals Inc Financial Data Overview
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Enanta Pharmaceuticals Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Enanta Pharmaceuticals Inc data using free add-ons & libraries
Get Enanta Pharmaceuticals Inc Fundamental Data
Enanta Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 64 806 K
- EBITDA: -93 036 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-11
- EPS/Forecast: -0.88
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Enanta Pharmaceuticals Inc News
New
ENT and Allergy Associates, LLP Welcomes Ethan Moritz, MD to Its Offices in Woodbury and Voorhees, NJ
Tarrytown, New York, Oct. 16, 2025 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA), the nation’s largest ENT, allergy, and audiology practice, is proud to announce that otolaryngologist...
Biggest stock movers Wednesday: LAC, NKE, and more
[Electronic highway billboard with government shutdown ahead warning] Richard Stephen Stock futures edged down Wednesday morning as the U.S. government shutdown commenced at midnight with the Senate ...
Enanta pharmaceuticals prices $65M common stock offering
* Enanta Pharmaceuticals (NASDAQ:ENTA [https://seekingalpha.com/symbol/ENTA]) has priced its public offering of 6.5M common shares at $10.00 per share for gross proceeds of $65.0M. * The company ...
Enanta shares rise despite RSV trial failing to meet main goal
[RSV, respiratory syncytial virus, human orthopneumovirus, contagious child disease] BeritK/iStock via Getty Images Enanta Pharmaceuticals (NASDAQ:ENTA [https://seekingalpha.com/symbol/ENTA]) shares ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.